Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug to see if it is safe and effective for people with cancer who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your blood test shows high levels of cardiac troponin, a sign of potential heart issues.I have POEMS syndrome.(For multiple myeloma participants only) You have a measurable disease according to specific guidelines.I have Waldenstrom's macroglobulinemia.I have amyloidosis.I have not needed IV treatments for an infection in the week before joining the study.I have not had a heart attack in the last 6 months and do not have severe heart failure.My blood counts are stable without needing transfusions or medications to help.My heart is functioning well.I am a woman who can have children and have a negative pregnancy test.My kidneys are working well.I had a stem cell transplant or been on immunosuppressives recently, or I show signs of graft-versus-host disease.I have plasma cell leukemia.I am not in another drug study, or if I am, it's approved by Amgen.I have recent signs of heart damage based on specific heart tests.I have a history of abnormal heart rhythms or cardiac arrest.If I am under 20 and in Japan, both I and my legal guardian have given consent.My AML has come back or didn't respond to treatment, and I can't use approved drugs in Japan.I am willing to have a bone marrow biopsy and aspirate.I can take care of myself but might not be able to do heavy physical work.The doctor thinks you will live for more than 3 months.My liver is working well.My multiple myeloma is of the Immunoglobulin M subtype.My multiple myeloma has returned or didn't respond after 2 treatments.I have not had a stroke or mini-stroke in the last 6 months.I have had COVID-19, but it's been discussed with the medical monitor.I have AML with over 5% bone marrow blasts and less than 25,000 white blood cells/ul.I had a stem cell transplant using my own cells less than 3 months ago.
- Group 1: AMG 176 - Part 3a
- Group 2: AMG 176 - Part 3c
- Group 3: AMG 176 - Part 3d
- Group 4: AMG 176 - Part 5
- Group 5: AMG 176 - Part 1a
- Group 6: AMG 176 - Part 1b
- Group 7: AMG 176 - Part 3b
- Group 8: AMG 176 - Part 4
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the desired outcomes of this research endeavor?
"As reported by Amgen, the main objective of this trial that will be evaluated over a 6-month period is to measure the incidence of clinically significant changes in clinical laboratory tests for Acute Myeloid Leukemia (AML) Part 3b. Additionally, secondary outcomes such as Multiple myeloma (MM) Part 1b overall response according to international myeloma working group uniform response criteria and AML Parts 3d Incidence of Clinically Significant Changes in Vital Signs, as well as 4 Event Free Survival (EFS), will also be monitored."
What have previous explorations revealed about AMG 176's efficacy?
"The initial research into AMG 176 was conducted in 2006 at the Chinese University of Hong Kong-Prince of Wales Hospital. Up to now, there have been 377 completed clinical studies dedicated to this drug and presently 187 trials are actively seeking participants with many being hosted out of Hackensack, New jersey."
Does this research accommodate elders more than sixty-five years of age?
"This experiment has a wide age range, from 18 to 85 years of age. Those younger than 18 can look into 471 trials while those older than 65 have the choice of 2074 studies."
Is it possible for me to join the ongoing clinical trial?
"This clinical trial will accept 175 participants aged 18 to 85 with multiple myeloma. In order to be eligible, individuals must meet the following requirements: have AML as defined by WHO persisting or recurring after one or more courses of treatment; life expectancy greater than 3 months; adequate hepatic function and ECOG performance status of no higher than 2 (except for those in Japan who are not eligible for approved anticancer drug therapy)."
Are there any opportunities for participants to enter this research study?
"According to clinicaltrials.gov, this study is still enrolling participants as of November 16th 2022. Initially posted on June 13th 2016, the trial has been regularly updated since then."
Are there various locales running this experiment across the state?
"This clinical trial has 11 locations available for patient recruitment, including John Theurer Cancer Center at Hackensack University Medical Center in New jersey, the University of Colorado in Aurora and University of Texas MD Anderson Cancer Centre located in Houston. Other 8 sites are also accepting applications from potential participants."
Is AMG 176 recognized by the Food and Drug Administration as safe for use?
"With only a small amount of data supporting its safety and efficacy, AMG 176 was assigned a score of 1 on the risk scale."
What medical conditions is AMG 176 employed to treat?
"AMG 176 is a popular treatment for chromomycosis and as an adjunct to complete blood count, induction chemotherapy, and vulvovaginal candidiasis."
Share this study with friends
Copy Link
Messenger